Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study

Crit Care Med. 1996 Mar;24(3):403-13. doi: 10.1097/00003246-199603000-00008.

Abstract

Objective: To evaluate the benefit of recombinant human growth hormone administration on muscle strength and duration of weaning in critically ill patients undergoing prolonged mechanical ventilation.

Design: Prospective, randomized, controlled, single-blind study.

Setting: Intensive care unit.

Patients: Twenty patients requiring > or = 7 days of mechanical ventilation for acute respiratory failure.

Intervention: Random assignment to receive either 0.43 IU (approximately 0.14 mg) recombinant growth hormone/kg body weight/day (treated group), or saline (nontreated group) for 12 days.

Measurements and main results: Nutritional support was guided by indirect calorimetry. Cumulative nitrogen balance was positive throughout the study period in the treated group 17.3 (44.9 +/- 17.3[SEM] g/12 days) vs. the nontreated group (-65.8 +/- 11.8 g/12 days) (p<.0001). Despite similar initial plasma concentrations, recombinant growth hormone supplementation resulted in marked increases in growth hormone, insulin like growth factor-1, and insulin concentrations (p<.05, .02, and .0001, respectively, vs. nontreated group). Body impedance determined net fat-free mass increased in the treated group (0.8 +/- 0.6 kg) vs. the nontreated group (-1.1 +/- O.5 kg) (p<.03). Initial peripheral muscle function, assessed by computer-controlled electrical stimulation of the adductor pollicis, was similarly lower in treated and nontreated groups than sex and age-matched normal controls, and decreased further during the study period. Arterial blood gases, cumulative total mechanical ventilation time, and number of hrs/day of mechanical ventilation during weaning were similar in both patient groups. Only three of the ten patients in each group were weaned from mechanical ventilation by day 12.

Conclusions: Daily administration of recombinant growth hormone in mechanically ventilated patients with acute respiratory failure promotes a marked nitrogen retention. However, this reaction is accompanied neither by an improvement in muscle strength nor by a shorter duration of ventilatory supports.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Disease
  • Aged
  • Combined Modality Therapy
  • Female
  • Growth Hormone / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Nutritional Support
  • Prospective Studies
  • Recombinant Proteins / therapeutic use
  • Respiration, Artificial*
  • Respiratory Insufficiency / physiopathology
  • Respiratory Insufficiency / therapy
  • Respiratory Muscles / drug effects*
  • Respiratory Muscles / physiopathology

Substances

  • Recombinant Proteins
  • Growth Hormone